FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045274368> ?p ?o ?g. }

• W2045274368 endingPage "465" @default.
• W2045274368 startingPage "459" @default.
• W2045274368 abstract "A pooled analysis was conducted in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia to examine the relationship between the postvoid residual urine (PVR) volume and various clinical characteristics and to assess the effect of alfuzosin, a clinically uroselective alpha(1)-blocker, on PVR volume and any other associated outcome.Nine hundred fifty-three patients, 42 to 89 years old, with a baseline PVR volume between 50 and 350 mL (mean 106 mL) were enrolled in 11 double-blind controlled studies and received either alfuzosin (n = 607) or placebo (n = 346) for 1 to 6 months. The relationships between the baseline PVR volume measured by transabdominal ultrasound and age, symptoms, maximum flow rate (Qmax), estimated bladder capacity, and prostate-specific antigen level were assessed. The changes in the PVR volume with treatment were evaluated in all available patients at three endpoints (1, 3, and 6 months).At baseline, a PVR volume of 100 mL or greater was observed in 60%, 47%, and 39% of patients with a Qmax less than 8, 8 to 11, and greater than 11 mL/s, respectively (P = 0.001). The bladder capacity was also significantly related to the Qmax (P = 0.0001). No relationship was found between PVR volume and age, symptoms, or prostate-specific antigen level. The changes in the PVR volume with treatment were related to the baseline PVR volume. However, at all endpoints and whatever the baseline PVR volume, the decreases in the PVR volume were significantly (P <0.01) greater with alfuzosin than with placebo. Acute urinary retention occurred in 7 patients (2 [0.3%] of 607 patients taking alfuzosin and 5 [1.4%] of 346 patients taking placebo); 6 of these 7 patients had a baseline PVR volume greater than 100 mL.In this population of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia, the PVR olume and bladder capacity were related to the baseline Qmax. Alfuzosin significantly reduced the PVR volume compared with placebo, and this effect was more marked in patients with a high PVR volume at baseline. Acute urinary retention occurred mainly in patients with a PVR volume greater than 100 mL and was less frequent in patients taking alfuzosin than in those taking placebo." @default.
• W2045274368 created "2016-06-24" @default.
• W2045274368 creator A5004207931 @default.
• W2045274368 creator A5030195416 @default.
• W2045274368 creator A5033422975 @default.
• W2045274368 creator A5049019006 @default.
• W2045274368 creator A5089050051 @default.
• W2045274368 date "2001-03-01" @default.
• W2045274368 modified "2023-09-27" @default.
• W2045274368 title "Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin" @default.
• W2045274368 cites W1206034219 @default.
• W2045274368 cites W1963673310 @default.
• W2045274368 cites W1977795164 @default.
• W2045274368 cites W1981384812 @default.
• W2045274368 cites W1983322061 @default.
• W2045274368 cites W1983391475 @default.
• W2045274368 cites W1994937084 @default.
• W2045274368 cites W2010260774 @default.
• W2045274368 cites W2017365683 @default.
• W2045274368 cites W2026238971 @default.
• W2045274368 cites W2036666325 @default.
• W2045274368 cites W2051440758 @default.
• W2045274368 cites W2058720768 @default.
• W2045274368 cites W2080372370 @default.
• W2045274368 cites W2082709973 @default.
• W2045274368 cites W2090839011 @default.
• W2045274368 cites W2129450531 @default.
• W2045274368 cites W2133609439 @default.
• W2045274368 cites W2156802695 @default.
• W2045274368 cites W2335425470 @default.
• W2045274368 cites W2395575737 @default.
• W2045274368 cites W4321060016 @default.
• W2045274368 cites W52004720 @default.
• W2045274368 doi "https://doi.org/10.1016/s0090-4295(00)01021-9" @default.
• W2045274368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11248620" @default.
• W2045274368 hasPublicationYear "2001" @default.
• W2045274368 type Work @default.
• W2045274368 sameAs 2045274368 @default.
• W2045274368 citedByCount "54" @default.
• W2045274368 countsByYear W20452743682012 @default.
• W2045274368 countsByYear W20452743682013 @default.
• W2045274368 countsByYear W20452743682014 @default.
• W2045274368 countsByYear W20452743682015 @default.
• W2045274368 countsByYear W20452743682016 @default.
• W2045274368 countsByYear W20452743682017 @default.
• W2045274368 countsByYear W20452743682018 @default.
• W2045274368 countsByYear W20452743682019 @default.
• W2045274368 countsByYear W20452743682022 @default.
• W2045274368 countsByYear W20452743682023 @default.
• W2045274368 crossrefType "journal-article" @default.
• W2045274368 hasAuthorship W2045274368A5004207931 @default.
• W2045274368 hasAuthorship W2045274368A5030195416 @default.
• W2045274368 hasAuthorship W2045274368A5033422975 @default.
• W2045274368 hasAuthorship W2045274368A5049019006 @default.
• W2045274368 hasAuthorship W2045274368A5089050051 @default.
• W2045274368 hasConcept C121608353 @default.
• W2045274368 hasConcept C126322002 @default.
• W2045274368 hasConcept C126894567 @default.
• W2045274368 hasConcept C142724271 @default.
• W2045274368 hasConcept C204787440 @default.
• W2045274368 hasConcept C27081682 @default.
• W2045274368 hasConcept C2776235491 @default.
• W2045274368 hasConcept C2776547966 @default.
• W2045274368 hasConcept C2777562237 @default.
• W2045274368 hasConcept C2779478474 @default.
• W2045274368 hasConcept C2780546585 @default.
• W2045274368 hasConcept C2781406297 @default.
• W2045274368 hasConcept C71924100 @default.
• W2045274368 hasConceptScore W2045274368C121608353 @default.
• W2045274368 hasConceptScore W2045274368C126322002 @default.
• W2045274368 hasConceptScore W2045274368C126894567 @default.
• W2045274368 hasConceptScore W2045274368C142724271 @default.
• W2045274368 hasConceptScore W2045274368C204787440 @default.
• W2045274368 hasConceptScore W2045274368C27081682 @default.
• W2045274368 hasConceptScore W2045274368C2776235491 @default.
• W2045274368 hasConceptScore W2045274368C2776547966 @default.
• W2045274368 hasConceptScore W2045274368C2777562237 @default.
• W2045274368 hasConceptScore W2045274368C2779478474 @default.
• W2045274368 hasConceptScore W2045274368C2780546585 @default.
• W2045274368 hasConceptScore W2045274368C2781406297 @default.
• W2045274368 hasConceptScore W2045274368C71924100 @default.
• W2045274368 hasIssue "3" @default.
• W2045274368 hasLocation W20452743681 @default.
• W2045274368 hasLocation W20452743682 @default.
• W2045274368 hasOpenAccess W2045274368 @default.
• W2045274368 hasPrimaryLocation W20452743681 @default.
• W2045274368 hasRelatedWork W1608169277 @default.
• W2045274368 hasRelatedWork W1978630268 @default.
• W2045274368 hasRelatedWork W2005938254 @default.
• W2045274368 hasRelatedWork W2013357874 @default.
• W2045274368 hasRelatedWork W2184873493 @default.
• W2045274368 hasRelatedWork W2330542927 @default.
• W2045274368 hasRelatedWork W2386204531 @default.
• W2045274368 hasRelatedWork W2414475439 @default.
• W2045274368 hasRelatedWork W3175503089 @default.
• W2045274368 hasRelatedWork W4382462402 @default.
• W2045274368 hasVolume "57" @default.
• W2045274368 isParatext "false" @default.

• next